Терапевтичні можливості підготовки жінок із безпліддям до ЕКЗ

Н. О. Данкович; О. М. Бабенко

doi:10.18370/2309-4117.2017.34.53-56

Authors

Н. О. Данкович Medical centre “Mother and child”, Kyiv, Ukraine https://orcid.org/0000-0002-3305-1547
О. М. Бабенко Medical centre “Mother and child”, Kyiv, Ukraine https://orcid.org/0000-0003-4542-7502

DOI:

https://doi.org/10.18370/2309-4117.2017.34.53-56

Keywords:

infertility, hyperprolactinemia, Agnus Castus, Prefemin

Abstract

The number of infertile couples in Ukraine reaches 20%. Elevated prolactin level is significant reason of fertility decline.

The aim of the study was to study the effectiveness of the Agnus Castus extract in infertil women with functional hyperprolactinemia who are preparing for IVF. This observational noninterventional cohort study included 30 women who applied for infertility treatment. All women were prescribed a drug that contained a standardized extract of Agnus Castus Ze 440, a tablet of which contains 20 mg of active ingredient, 1 tablet once a day for 3 months.

In the course of the study there was a significant reduction in the severity of complaints as a part of premenstrual syndrome, according to the patients assessment using a visual analogue scale. So, after a month of treatment, half as much patients had irritability and mood swings, 1.5 times less often had headache, breast pain, attacks of anger, and almost 3 times – bloating.

Such positive dynamics persisted with further therapy: breast pain and bloating almost disappeared (scores of 1.33 ± 0.10 points and 1.18 ± 0.05 points, p < 0.05); other complaints were low intensity (scores of 2–3 points). The level of prolactin in examined women was 47.12 ± 5.34 ng/ml before the start of treatment, and after completion of the treatment it decreased more than two times – 19.08 ± 3.47 ng/ml (p < 0.05).

The authors concluded that the use of standardized extract of the Agnus Castus Ze 440 (Prefemin) in women with infertility and functional hyperprolactinemia was highly effective and led to normalization of prolactin level in 76.66% of cases and reduction of PMS clinical manifestations in majority of patients. Thus, studied drug can be considered as an effective therapeutic option in patients before IVF in order to reduce the pharmacological burden and improve the results of infertility treatment.

Author Biographies

Н. О. Данкович, Medical centre “Mother and child”, Kyiv

MD, professor, general director

О. М. Бабенко, Medical centre “Mother and child”, Kyiv

PhD, obstetrician gynecologist

References

Dankovych, N.O., Vorobiy-Vyhovska, V.M. “The causes and forms of infertility. Current treatment options.” Women’s Health 3 (2013): 192–7.
Parashchuk, Y.S., Kalinovska, O.I., Gryshchenko, M.G., Parashchuk, V.Y. Infertility in marriage: manual. Kharkiv. Kharkiv National Medical University (2014): 124 p.
Radzinskyi, V.E., Simonovskaya, H.Y. Phytotherapy in obstetrics and gynecology. A new century is a new ideology. The concept of phytoniring as a stage in the development of phytotherapy. Newsletter. Ed. 2nd, corrected. Moscow. Editorial office of the StatusPraesens journal (2015): 16 p.
Rafieian-Kopaei, M., Movahedi, M. “Systematic Review of Premenstrual, Postmenstrual and Infertility Disorders of Vitex Agnus Castus.” Electronic Physician 9.1 (2017): 3685–9.
Doldi, N., Papaleo, E., De Santis, L., Ferrari, A. “Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs.” Gynecol Endocrinol 14.6 (2000): 437–41.
National consensus on the management of patients with hyperprolactinemia (2016). Reproductive endocrinology 4.30 (2016): 8–18.
Jarry, H., Leonhardt, S., Gorkow, C., Wuttke, W. “In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay.” Exp Clin Endocrinol 102 (1994): 448–54.
Wuttke, W., Jarry, H., Christoffel, V., et al. “Chaste tree (Vitex agnus castus) – pharmacology and clinical indications.” Phytomedicine 10 (2003): 335–48.
Gerhard, I.I., Patek, A., Monga, B., et al. “Mastodynon (R) bei weiblicher Sterilitat.” Forsch Komplementarmed 5 (1998): 272–8.
Eltbogen, R., et al. “Vitex-agnus-castus-Extrakt (Ze 440) zur Symptom-behandlung bei Frauen mit menstruellen Zyklusstörungen.” Journal für Gynäkologische Endokrinologie 25.2 (2015): 10–15.
Smetnik, V.P., Butareva, L.B. “Experience of application of phytodrug «Cyclodinone» in patients with deficiency of the function of the yellow body and hyperprolactinemia.” Problems of reproduction 5 (2005): 1–4.
Tatarchuk, T.F., Tutchenko, T.N. “Correction of hyperprolactinemia in the complex treatment of endometrial hyperplasia.” Reproductive endocrinology 2 (2013).
Atmaca, M., et al. “Fluoxetine versus Vitex Agnus castus extract in the treatment of premenstrual dysphoric disorder.” Human Psychopharmacology Clin Exp 18 (2003): 191–5.
Schellenberg, R., et al. “Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome.” Phytomedicine 19.14 (2012): 1325–31.
Wuttke, W., Seidlova-Wuttke, D., Jarry, H., Artymuk, N. “Der Stellenwert des Mönchspfeffers (Vitex agnus-castus) in der gynäkologischen Endokrinologie.” Zeitschrift Phytotherapie 31 (2010): 294–8.
Wuttke, W., et al. “Behandlung zyklusabhängiger Brustschmerzen mit einem Agnus castus haltigen Arzneimittel.” Geburtshilfe und Frauenheilkunde 57 (1997): 569–74.